Creative Biolabs provides diverse immunotherapy modalities, quantifying ADC, BsAb, and CAR-T efficacy. We offer antibody engineering, cancer vaccines, and oncolytic virus services.
Learn More →Therapeutic Modality Portfolio Services
Creative Biolabs provides a unified ecosystem for the design, engineering, and validation of diverse therapeutic modalities. By moving beyond "one-target, one-drug" models, we provide clients with synergistic combinations that address disease heterogeneity and adaptive resistance. Whether you are developing bispecific antibodies (BsAbs) to target emerging checkpoints like VISTA and TIM-3 or engineering CAR-NK cells for solid tumors, our platform delivers high-potency leads with optimized pharmacological profiles. Our approach is designed to transform "cold" tumors into immune-active "hot" zones by strategically pairing biological agents with precision delivery systems.
Background Featured Services Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Scientific Foundation: Multimodal Synergy in Modern Biomedicine
The therapeutic modality portfolio represents a critical strategic shift toward multimodal precision medicine, moving beyond the limitations of single-agent therapies. Grounded in contemporary research into the "hot" versus "cold" tumor dichotomy, this approach leverages advanced co-occurrence analysis of therapeutic targets, such as m6A epigenetic modifiers, STING agonists, and next-generation checkpoints like TIM-3. In a research landscape where monotherapies frequently fail due to adaptive resistance mechanisms, our portfolio approach enables the simultaneous targeting of diverse inhibitory pathways.
Integrated Precision Engineering
Creative Biolabs offers an expansive suite of specialized platforms designed to overcome the most stubborn barriers in drug discovery. By integrating disparate technologies into a cohesive portfolio, we enable the development of "smart" therapeutics that react dynamically to the pathological environment.
Modality
Synthetic Gene Circuits for Cancer Immunotherapy - Turning Cancer Cells Against Themselves
Creative Biolabs develops synthetic gene circuits to engineer cancer cells for self-destruction, quantifying lymphangiogenesis and T-cell activation. We offer viral and CRISPR-based engineering to optimize immunomodulatory circuits and outcomes.
Learn More →Cytokine Immunotherapy Development
Creative Biolabs provides cytokine immunotherapy development services, quantifying half-life extension, bioactivity, and targeted delivery. We optimize interleukins, interferons, and chemokines to enhance anti-tumor immunity and ensure preclinical-to-clinical success.
Learn More →Antibody-directed Enzyme Prodrug Therapy (ADEPT) Solutions
Creative Biolabs provides ADEPT solutions, optimizing antibody-enzyme conjugates and prodrug design. We evaluate tumor-targeting specificity, enzymatic conversion kinetics, and systemic clearance to ensure high-efficacy site-specific activation and minimized toxicity.
Learn More →Innovative Sono-Immunotherapy Solutions
Creative Biolabs provides innovative sono-immunotherapy solutions, quantifying ultrasound-triggered drug release and sonodynamic-induced immune activation. We offer nanocarrier engineering and TME remodeling assays to optimize tumor-targeted synergy.
Learn More →Regulatory T Cell Therapy Development
Creative Biolabs provides regulatory T cell therapy development, quantifying suppressive activity and lineage stability. We offer CAR-Treg and TCR-Treg engineering to optimize immune tolerance and project success.
Learn More →Autologous Fibroblast (AF) Therapy Development
Creative Biolabs provides autologous fibroblast therapy development, quantifying lentiviral vector integration and target protein expression. We offer cell expansion and genetic modification to optimize personalized gene delivery.
Learn More →Antigen-Presenting Cell & Immunomodulatory Therapy Development
Creative Biolabs provides antigen-presenting cell and immunomodulatory therapy development services, quantifying dendritic cell maturation and T-cell activation. We offer bespoke assay panels to optimize antigen presentation.
Learn More →Specialized Therapeutic Modality Development
Creative Biolabs offers specialized therapeutic development, quantifying the efficacy of venom peptides, immunotoxins, and ICD inducers. We provide PRR agonist optimization and multiplexed gene activation to drive targeted immunotherapy.
Learn More →Neoantigen-based Cancer Immunotherapy Development
Creative Biolabs provides neoantigen-based immunotherapy development, quantifying mutation identification and HLA binding affinity. We offer personalized vaccine design and T-cell response validation to optimize tumor-specific targeting.
Learn More →Advanced Gene Circuit & Cell Culture Platforms
Creative Biolabs provides advanced gene circuit and cell culture platforms, quantifying synthetic regulatory logic and dynamic cellular responses. We offer CRISPR-based circuits and complex co-culture models to optimize precision oncology.
Learn More →Advanced Nanomedicine & Conjugate Development
Creative Biolabs provides advanced nanomedicine and conjugate development services, optimizing lipid nanoparticles, polymeric micelles, and ligand-functionalized conjugates. We ensure precise targeting, enhanced bioavailability, and robust manufacturing to accelerate your innovative drug delivery programs.
Learn More →Unlock the Potential of Multimodal Synergy—Request a Specialist Consultation to Design Your Lead Strategy
Workflow
Our service workflow is a meticulously structured process designed to translate complex biological concepts into validated therapeutic candidates.
Publication
This review examines the rationale and clinical evidence for combining immunotherapies (checkpoint inhibitors, adoptive cell transfer, cancer vaccines) with conventional treatments (chemotherapy, radiotherapy) to enhance anticancer efficacy. It highlights synergistic mechanisms, such as T cell reinvigoration, abscopal effects, and overcoming resistance, while addressing challenges including toxicity, high costs, and heterogeneous responses. The authors discuss ongoing trials and the need for optimized dosing and sequencing to improve patient outcomes.
Fig.1 Mechanisms of antitumor activity of CTLA-4–targeting antibodies. 1
Why Choose Us?
Creative Biolabs stands at the intersection of deep-rooted biological expertise and cutting-edge engineering innovation. Our unique strength lies in our ability to quantify complex biological interactions, ranging from HLA binding affinity to the lineage stability of engineered Treg therapies, with extreme precision. We leverage a data-driven approach, drawing from a vast internal library of successful modality pairings to guide our combinatorial logic. By choosing Creative Biolabs, you gain access to proprietary platforms like our CRISPR-driven gene circuits and sonodynamic remodeling assays.
Empower Your Pipeline with 20 Years of Specialized Expertise—Get a Customized Quote for Your Project Now
FAQs
How do you decide which modalities to combine in a portfolio?
At Creative Biolabs, we use a combination of biological rationale and data-driven analysis. We analyze research data to find co-occurring concepts to ensure your combination addresses redundant escape pathways.
Can you work with proprietary targets we have already identified?
Absolutely. We can integrate your proprietary antibodies or small molecules into our advanced conjugate (ADC/ADEPT) or gene circuit platforms to enhance their therapeutic value and extend their potential applications.
How do you ensure the stability of Treg or CAR-NK therapies?
Creative Biolabs includes rigorous quantification of lineage stability and suppressive potency using specialized assays that simulate the hostile conditions of the TME, ensuring the cells don't "switch" phenotype post-infusion.
Customer Review
-
Superior Synergy Quantification
Using Creative Biolabs' therapeutic modality portfolio in our research has significantly facilitated the identification of effective bispecific pairings for VISTA and PD-L1, moving our project into animal trials months ahead of schedule. - Dr. Elena V** -
Exceptional Precision in Gene Logic
The CRISPR-based synthetic circuits provided by the team allowed us to program cell therapies with unprecedented 'AND' logic. The lineage stability data for our Treg project was particularly impressive. - Marcus S**
Related Services
ADC Antibody Screening Service
Creative Biolabs provides ADC antibody screening, quantifying antigen specificity, binding affinity, and internalization. We offer phage display, antibody humanization, and Anti-Ab ADC assays to identify high-potency leads for targeted therapy.
Learn More →Linker and Payload Synthesis Service
Creative Biolabs provides custom ADC linker and payload synthesis, quantifying pH-sensitive, disulfide, and peptide-cleavable stability. We offer microtubule destabilizers and DNA-targeting agents via advanced conjugation platforms to optimize therapeutic windows.
Learn More →How to Contact Creative Biolabs
By combining deep scientific expertise in emerging targets with innovative technologies like ADEPT, sono-immunotherapy, and synthetic gene circuits, we provide the blueprints for the next generation of blockbuster therapeutics. Whether your goal is to overcome drug resistance or engineer a first-in-class cell research project, our end-to-end platform is built to deliver.
Contact Creative Biolabs today to speak with our specialists and learn how we can architect your therapeutic future.
Reference
- Barbari, Cody, et al. "Immunotherapies and combination strategies for immuno-oncology." International journal of molecular sciences 21.14 (2020): 5009. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms21145009
Download our brochureLoading case studies...
Online Inquiry